Black Diamond Therapeutics, Inc.
BDTXHealthcare|Biotechnology|US
$1.74
+0.07 (+4.52%)
DCF Value
$10.92
Tangible Book / Share
$1.68
Cash / Share
$1.93
Clinical Trials (4)
| Trial | Conditions | Phase | Status | Enrollment | Design | Drug |
|---|---|---|---|---|---|---|
| NCT07326566 Study of Silevertinib With Temozolomide for the Treatment of Newly Diagnosed GBM With Unmethylated MGMT and EGFRvIII | Glioblastoma (GBM), Newly Diagnosed Glioblastoma | P2 | Recruiting | 162 | RCT, Open-label | silevertinib in combination with temozolomide, temozolomide (TMZ) |
| NCT05256290 Phase 1/2 Study of Silevertinib (BDTX-1535) in Patients With Glioblastoma or Non-Small Cell Lung Cancer With EGFR Mutations | Non-Small Cell Lung Cancer, Advanced Non-Small Cell Squamous Lung Cancer | P1P2 | Active | 200 | Open-label | silevertinib (BDTX-1535) monotherapy |
| NCT04209465 A Study of BDTX-189, an Orally Available Allosteric ErbB Inhibitor, in Patients With Advanced Solid Tumors. | Solid Tumor | P1 | Terminated | 91 | Open-label | BDTX-189 |
| NCT03930264 Bioequivalence of Azathioprine Suspension 10 mg/mL (Jayempi) Versus Azathioprine Tablet 50mg (Imurek®) | Therapeutic Equivalency | P1 | Completed | 30 | RCT, Single-blind | Azathioprine 50Mg Tab, Azathioprine 10mg/mL oral suspension |